Filing Details

Accession Number:
0001562180-20-004358
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-09 16:17:35
Reporting Period:
2020-06-05
Accepted Time:
2020-06-09 16:17:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1517022 Akebia Therapeutics Inc. AKBA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1280044 Maxine Gowen C/o Akebia Therapeutics, Inc.
245 First Street
Cambridge MA 02142
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-05 13,700 $0.00 28,700 No 4 A Direct
Common Stock Disposition 2020-06-08 4,567 $12.05 24,133 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to buy) Acquisiton 2020-06-05 20,100 $0.00 20,100 $11.96
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,100 2021-06-05 2030-06-05 No 4 A Direct
Footnotes
  1. The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
  2. This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019.
  3. Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.